ArticleInternational journal of oncology2016
Overexpression of the S100A2 protein as a prognostic marker for patients with stage II and III colorectal cancer.
Article in International journal of oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 36 citations in OpenAlex.
- Role of S100 family proteins in colorectal cancer (CRC): an overview of their potential function as new biomarkers and therapeutic agents.Expert reviews in molecular medicine · 2025Review
- S100A2 activation promotes interstitial fibrosis in kidneys by FoxO1-mediated epithelial-mesenchymal transition.Cell biology and toxicology · 2024Article
- Protein expression of S100A2 reveals it association with patient prognosis and immune infiltration profile in colorectal cancer.Journal of Cancer · 2023Article
- Increased Expression of the RBPMS Splice Variants Inhibits Cell Proliferation in Ovarian Cancer Cells.International journal of molecular sciences · 2022Article
- Influence of S100A2 in Human Diseases.Diagnostics (Basel, Switzerland) · 2022Review
- High expression of S100A2 predicts poor prognosis in patients with endometrial carcinoma.BMC cancer · 2022Article
- Article
- miR-325-3p Promotes the Proliferation, Invasion, and EMT of Breast Cancer Cells by Directly Targeting S100A2.Oncology research · 2021Article
- Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis.Journal of experimental & clinical cancer research : CR · 2021Article
- Integrative analysis identifies an immune-relevant epigenetic signature for prognostication of non-G-CIMP glioblastomas.Oncoimmunology · 2021Article
- S100A16 suppresses the proliferation, migration and invasion of colorectal cancer cells in part via the JNK/p38 MAPK pathway.Molecular medicine reports · 2021Article
- The Importance of Sex in the Discovery of Colorectal Cancer Prognostic Biomarkers.International journal of molecular sciences · 2021Article
- Tissue mRNA for S100A4, S100A6, S100A8, S100A9, S100A11 and S100P Proteins in Colorectal Neoplasia: A Pilot Study.Molecules (Basel, Switzerland) · 2021Article
- Comprehensive Profiling Reveals Distinct Microenvironment and Metabolism Characterization of Lung Adenocarcinoma.Frontiers in genetics · 2021Article
- Comprehensive analysis of the expression and prognosis for S100 in human ovarian cancer: A STROBE study.Medicine · 2020Article
- Identifying four DNA methylation gene sites signature for predicting prognosis of osteosarcoma.Translational cancer research · 2020Article
- A network-based predictive gene expression signature for recurrence risks in stage II colorectal cancer.Cancer medicine · 2020Article
- An Integrated Bioinformatic Analysis of the S100 Gene Family for the Prognosis of Colorectal Cancer.BioMed research international · 2020Article
- Dysregulation of pseudogene/lncRNA-hsa-miR-363-3p-SPOCK2 pathway fuels stage progression of ovarian cancer.Aging · 2019Article
- Prognostic values of S100 family members in ovarian cancer patients.BMC cancer · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to identify a novel prognostic biomarker related to recurrence in stage II and III colorectal cancer (CRC) patients. Stage II and III CRC tissue mRNA expression was profiled using an Affymetrix Gene Chip, and copy number profiles of 125 patients were generated using an Affymetrix 250K Sty array. Genes showing both upregulated expression and copy number gains in cases involving recurrence were extracted as candidate biomarkers. The protein expression of the candidate gene was assessed using immunohistochemical staining of tissue from 161 patients. The relationship between protein expression and clinicopathological features was also examined. We identified 9 candidate genes related to recurrence of stage II and III CRC, whose mRNA expression was significantly higher in CRC than in normal tissue. Of these proteins, the S100 calcium-binding protein A2 (S100A2) has been observed in several human cancers. S100A2 protein overexpression in CRC cells was associated with significantly worse overall survival and relapse-free survival, indicating that S100A2 is an independent risk factor for stage II and III CRC recurrence. S100A2 overexpression in cancer cells could be a biomarker of poor prognosis in stage II and III CRC recurrence and a target for treatment of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.